Antiretroviral drug interactions

Edward P. Acosta, Courtney V. Fletcher

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

It has recently been estimated that persons with the acquired immunodeficiency syndrome (AIDS) receive on average 5.6 prescription medications throughout their disease course, and this number may be as high as 9 [1,2]. With the development and testing of new antiretroviral agents and drugs for opportunistic infections associated with human immunodeficiency virus (HIV) disease, the issue of polypharmacy and multiple drug interactions will become increasingly complex. Since antiretroviral therapy and treatment or prophylaxis of opportunistic infections is lifelong, the nature of these interactions requires delineation to provide an optimal pharmacologic strategy for the use of these agents in combination. This article will address antiretroviral drug interactions from a pharmacokinetic and pharmacodynamic perspective. A background on the clinical pharmacology of antiretroviral agents is provided as is a discussion of selected interations.

Original languageEnglish (US)
Pages (from-to)73-83
Number of pages11
JournalInternational Journal of Antimicrobial Agents
Volume5
Issue number2
DOIs
StatePublished - Apr 1995

Fingerprint

Anti-Retroviral Agents
Opportunistic Infections
Drug Interactions
Polypharmacy
Clinical Pharmacology
Virus Diseases
Prescriptions
Acquired Immunodeficiency Syndrome
Pharmacokinetics
HIV
Therapeutics
Pharmaceutical Preparations

Keywords

  • Antiretroviral agent
  • Drug interaction
  • HIV-infection

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Antiretroviral drug interactions. / Acosta, Edward P.; Fletcher, Courtney V.

In: International Journal of Antimicrobial Agents, Vol. 5, No. 2, 04.1995, p. 73-83.

Research output: Contribution to journalArticle

@article{5d320ee77fbb4590affb8739d1700e3b,
title = "Antiretroviral drug interactions",
abstract = "It has recently been estimated that persons with the acquired immunodeficiency syndrome (AIDS) receive on average 5.6 prescription medications throughout their disease course, and this number may be as high as 9 [1,2]. With the development and testing of new antiretroviral agents and drugs for opportunistic infections associated with human immunodeficiency virus (HIV) disease, the issue of polypharmacy and multiple drug interactions will become increasingly complex. Since antiretroviral therapy and treatment or prophylaxis of opportunistic infections is lifelong, the nature of these interactions requires delineation to provide an optimal pharmacologic strategy for the use of these agents in combination. This article will address antiretroviral drug interactions from a pharmacokinetic and pharmacodynamic perspective. A background on the clinical pharmacology of antiretroviral agents is provided as is a discussion of selected interations.",
keywords = "Antiretroviral agent, Drug interaction, HIV-infection",
author = "Acosta, {Edward P.} and Fletcher, {Courtney V.}",
year = "1995",
month = "4",
doi = "10.1016/0924-8579(94)00063-Z",
language = "English (US)",
volume = "5",
pages = "73--83",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Antiretroviral drug interactions

AU - Acosta, Edward P.

AU - Fletcher, Courtney V.

PY - 1995/4

Y1 - 1995/4

N2 - It has recently been estimated that persons with the acquired immunodeficiency syndrome (AIDS) receive on average 5.6 prescription medications throughout their disease course, and this number may be as high as 9 [1,2]. With the development and testing of new antiretroviral agents and drugs for opportunistic infections associated with human immunodeficiency virus (HIV) disease, the issue of polypharmacy and multiple drug interactions will become increasingly complex. Since antiretroviral therapy and treatment or prophylaxis of opportunistic infections is lifelong, the nature of these interactions requires delineation to provide an optimal pharmacologic strategy for the use of these agents in combination. This article will address antiretroviral drug interactions from a pharmacokinetic and pharmacodynamic perspective. A background on the clinical pharmacology of antiretroviral agents is provided as is a discussion of selected interations.

AB - It has recently been estimated that persons with the acquired immunodeficiency syndrome (AIDS) receive on average 5.6 prescription medications throughout their disease course, and this number may be as high as 9 [1,2]. With the development and testing of new antiretroviral agents and drugs for opportunistic infections associated with human immunodeficiency virus (HIV) disease, the issue of polypharmacy and multiple drug interactions will become increasingly complex. Since antiretroviral therapy and treatment or prophylaxis of opportunistic infections is lifelong, the nature of these interactions requires delineation to provide an optimal pharmacologic strategy for the use of these agents in combination. This article will address antiretroviral drug interactions from a pharmacokinetic and pharmacodynamic perspective. A background on the clinical pharmacology of antiretroviral agents is provided as is a discussion of selected interations.

KW - Antiretroviral agent

KW - Drug interaction

KW - HIV-infection

UR - http://www.scopus.com/inward/record.url?scp=0028937855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028937855&partnerID=8YFLogxK

U2 - 10.1016/0924-8579(94)00063-Z

DO - 10.1016/0924-8579(94)00063-Z

M3 - Article

C2 - 18611653

AN - SCOPUS:0028937855

VL - 5

SP - 73

EP - 83

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 2

ER -